HRA00184-C004 / Jiangsu Hengrui Pharma - LARVOL DELTA

HRA00184-C004, preclinical characterization of a novel tissue factor-targeted antibody-drug conjugate (AACR 2024) - "Notably, neither coagulation disorder nor skin rash was observed, which are superior to the historical NHP data reported by Tivdak. In conclusion, with the encouraging efficacy in preclinical study and promising safety profiles in NHPs, HRA00184-C004 has demonstrated the best-in-class potential and is scheduled to advance into clinical development."

Preclinical • Cervical Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer